The PFAS Series
A clinical guide to forever chemicals, the research behind them, and what can actually be done about the ones already in your body.
5 Articles · by Allen P. Green, MD
Over the past decade, the evidence linking PFAS to kidney and testicular cancer, thyroid disease, elevated cholesterol, cardiovascular and liver disease, immune dysfunction, and reduced fertility has accumulated steadily. What was missing until recently was any controlled evidence that the PFAS already in the human body could be meaningfully reduced.
A 2022 Australian randomized clinical trial, published in JAMA Network Open, changed that. Subsequent mechanistic research, including a March 2026 paper from the University of Colorado Anschutz identifying PFDA as the most harmful PFAS during fetal development, has sharpened the clinical picture considerably.
This series organizes what the science now supports, what it doesn’t yet support, and where the conversation should land for patients trying to make informed decisions. Part 1 is the new entry point for readers new to the topic. Parts 2, 3, and 4 were originally published as standalone posts in October 2025 and have been updated for the series. Part 5 arrives in the coming weeks.
The Complete Investigation
The PFAS Problem
What forever chemicals are, why they persist, and what we can actually do about them
The overview. Carbon-fluorine bond chemistry, biological half-lives, scope of human exposure, and the intervention question framed honestly. Entry point for readers new to the topic.
TPE for Detoxification
The broader environmental medicine frame. PFAS in the context of heavy metals, microplastics, and the general class of persistent lipophilic toxins. Where plasma compartment removal fits in the intervention landscape.
The Jersey PFAS Crisis
Geography as exposure. The public health case of one of the most contaminated populations in the United States, and the anti-bloodletting argument for why targeting plasma matters more than targeting blood.
The Hidden Risk of Weight Loss
The unintended mobilization problem. Fat loss releases stored persistent organic pollutants into circulation, and the Australian firefighter RCT suggests plasma-based removal is the most efficient countermeasure studied to date.
Two independent research teams converged on the same PFAS compound as the worst actor, from completely different clinical endpoints. That kind of convergence is how scientific consensus begins to form.
Explore Your Options
If you or a loved one has concerns about PFAS exposure, a discovery call with Dr. Green can help you understand whether therapeutic apheresis is appropriate for your situation. There is no obligation, and the conversation is complimentary.
Looking for the shorter, practice-voice treatment? Read the companion post on Global Apheresis →